HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Clinical trial NCT06822972 · RECRUITING

Trial details

NCT number: NCT06822972
Sponsor: Duke University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma in Relapse Multiple Myeloma, Refractory

Start date: 2025-08-22
Primary completion: 2026-12-31
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.